How Pancreatic Tumors Hijack Immune Cells to Dodge Their Own Death
Resident macrophages shield aggressive pancreatic cancer cells from ferroptosis by donating a selenium transport protein, fueling invasion and metastasis.
Summary
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, partly because tumor cells evade natural cell-death programs. This study reveals a surprising mechanism: immune cells already living in normal pancreatic tissue — called resident tissue macrophages — cluster at tumor borders and donate a selenium-carrying protein called Selenop directly to the most aggressive cancer cells. This selenium delivery prevents a form of oxidative cell death known as ferroptosis, allowing invasive tumor cells to survive and spread. Blocking this protein transfer in mouse models reduced tumor growth and metastasis. Human PDAC tissue showed the same pattern, suggesting this is a conserved survival strategy. The findings point to macrophage-derived selenium supply as a new therapeutic target in one of the hardest-to-treat cancers.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, and a key reason is the tumor microenvironment's ability to suppress natural anti-cancer mechanisms, including ferroptosis — an iron-dependent form of programmed cell death driven by lipid peroxidation. Understanding how PDAC evades ferroptosis could open new treatment avenues.
Researchers from Ruijin Hospital and collaborating institutions combined single-cell profiling, spatial analysis, lineage tracing, RTM depletion, and selenium tracing to map the roles of two distinct macrophage populations inside PDAC tumors. They distinguished resident tissue macrophages (RTMs), which colonize the pancreas before tumors form, from monocyte-derived macrophages recruited after tumor onset.
The central finding is that RTMs preferentially accumulate at the tumor border, where the most invasive, epithelial-mesenchymal transition (EMT)-high cancer cells reside. RTMs transfer Selenop, a selenium transporter protein, to EMT-high tumor cells via LRP8-dependent uptake. This delivery increases tumor-cell selenium availability, limits lipid peroxidation — the molecular trigger of ferroptosis — and effectively creates a protective 'selenium niche' that shields the most aggressive cancer cells from oxidative death.
RTM-specific Selenop deletion or tumor-cell Lrp8 disruption reduced EMT and tumor progression in mouse models, while pharmacological inhibition of ferroptosis reversed the anti-tumor effect of RTM depletion, confirming that ferroptosis protection is the primary mechanism at work. Human PDAC tissue showed border-enriched SEPP1+ RTMs adjacent to EMT-high tumor cells, suggesting a conserved macrophage-derived selenium niche.
These findings reframe how the immune microenvironment sustains pancreatic cancer, identifying the RTM-Selenop-LRP8 axis as a potential drug target. Limitations include reliance on the abstract for review, without access to full quantitative data, dosing specifics, or full in-vivo model details.
Key Findings
- Resident tissue macrophages cluster at PDAC tumor borders and transfer the selenium transporter Selenop to invasive cancer cells.
- LRP8-mediated selenium uptake by tumor cells suppresses lipid peroxidation, shielding them from ferroptosis-mediated death.
- Deleting RTM-specific Selenop or tumor-cell LRP8 reduced epithelial-mesenchymal transition, tumor growth, and metastasis in mice.
- Ferroptosis inhibition fully reversed the anti-tumor effect of RTM depletion, confirming selenium supply as the key mechanism.
- Human PDAC tissue shows the same border-enriched SEPP1+ macrophage pattern near aggressive tumor cells, indicating clinical relevance.
Methodology
The study used single-cell transcriptomic profiling, spatial transcriptomics, genetic lineage tracing, RTM depletion models, and selenium isotope tracing in murine PDAC models. Human PDAC tumor sections were analyzed to validate spatial co-localization of SEPP1+ macrophages and EMT-high tumor cells. Genetic knockout models for RTM-specific Selenop and tumor-cell Lrp8 were employed to establish causality.
Study Limitations
This summary is based on the published abstract; the full paper's quantitative data, statistical methods, and complete experimental details were not reviewed. Mouse model findings may not fully recapitulate human PDAC biology, and RTM depletion strategies carry potential off-target immunological effects. Co-authors have declared a pending patent related to this work, which represents a potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: